$HEIA (-1.33%)
$EL (+0.5%)
$NUE (-0.32%)
$CDNS (+0.05%)
$WM (+1.03%)
$MSFT (-0.15%)
$V (+0.99%)
$OR (+0.23%)
$AZN (+2.18%)
$MRK (-0.26%)
$PG (-0.26%)
$SBUX (-0.84%)
$BCS (+1.42%)
$META (-2.33%)
$BABA (-0.87%)
$QCOM (-0.19%)
$AIR (+0.85%)
$HSBC (+1.24%)
$GSK (-1.92%)
$MBG (+1.52%)
$F (+2.98%)
$AAPL (-0.07%)
$AMZN (-1.27%)
$MA (+0.71%)
$7203 (+0.8%)
$SHEL (+1.6%)
$005930
$SNY (+1.41%)
$CMCSA (+1.46%)
$COIN (+1.92%)
$NET (-4.06%)
$XOM (+1.38%)
$CVX (-0.08%)
$CS (-1.04%)
$NTDOY (-0.27%)
$CL (-0.54%)
$DTG (+0.79%)
$UNH (+1.57%)
- Markets
- Stocks
- Sanofi ADR Representing 1 1/2
- Forum Discussion
Discussion about SNY
Posts
2Quarterly figures 28.07-01.08



Sanofi reported earnings Q4 FY2024 results ended on December 31, 2024
- Revenue: €10.56B, +10.3% YoY at CER
- Net income: €683M vs -€555M in Q4 2023
- Business EPS: €1.31, -11.0% YoY at CER
- Full year revenue: €41.1B, +11.3% YoY at CER
CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."
🌱Revenue & Growth
- US sales: €5.15B, +13.3% YoY at CER
- Europe sales: €2.43B, +6.0% YoY at CER
- Rest of World: €2.98B, +8.8% YoY at CER
- Dupixent sales: €3.46B, +16.0% YoY at CER
- Vaccines sales: €2.18B, +10.8% YoY at CER
💰Profits & Financials
- Gross margin: 74.3%, -2.5pp YoY
- Business operating income: €2.08B, -7.7% YoY at CER
- Free cash flow: €2.34B, -25.5% YoY
- R&D expenses: €2.26B, +24.4% YoY
📌Business Highlights
- Received 14 regulatory approvals of medicines and vaccines in 2024
- Beyfortus achieved blockbuster status with €1.7B sales in first full year
- Plans to sell controlling stake in Opella consumer health business
🔮Future Outlook
- 2025 sales growth expected at mid-to-high single-digit percentage at CER
- Expects strong rebound in business EPS with low double-digit growth at CER
- Plans €5B share buyback program in 2025
- Dupixent sales expected to reach around €22B by 2030
Trending Securities
Top creators this week